- Home
- UGI vs BPMC Comparison
UGI vs BPMC Comparison
Compare UGI & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGI
- BPMC
- Stock Information
- Founded
- UGI 1940
- BPMC 2008
- Country
- UGI United States
- BPMC United States
- Employees
- UGI N/A
- BPMC N/A
- Industry
- UGI Natural Gas Distribution
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- UGI Utilities
- BPMC Health Care
- Exchange
- UGI Nasdaq
- BPMC Nasdaq
- Market Cap
- UGI 7.7B
- BPMC 8.3B
- IPO Year
- UGI N/A
- BPMC 2015
- Fundamental
- Price
- UGI $35.58
- BPMC $129.32
- Analyst Decision
- UGI Buy
- BPMC Buy
- Analyst Count
- UGI 3
- BPMC 20
- Target Price
- UGI $31.33
- BPMC $127.82
- AVG Volume (30 Days)
- UGI 1.8M
- BPMC 3.3M
- Earning Date
- UGI 08-06-2025
- BPMC 07-31-2025
- Dividend Yield
- UGI 4.19%
- BPMC N/A
- EPS Growth
- UGI N/A
- BPMC N/A
- EPS
- UGI 2.46
- BPMC N/A
- Revenue
- UGI $7,318,000,000.00
- BPMC $562,121,000.00
- Revenue This Year
- UGI $6.56
- BPMC $44.46
- Revenue Next Year
- UGI $8.97
- BPMC $32.78
- P/E Ratio
- UGI $14.43
- BPMC N/A
- Revenue Growth
- UGI N/A
- BPMC 99.19
- 52 Week Low
- UGI $22.71
- BPMC $73.04
- 52 Week High
- UGI $36.74
- BPMC $129.49
- Technical
- Relative Strength Index (RSI)
- UGI 49.20
- BPMC 76.79
- Support Level
- UGI $34.98
- BPMC $128.06
- Resistance Level
- UGI $35.89
- BPMC $129.49
- Average True Range (ATR)
- UGI 0.56
- BPMC 0.27
- MACD
- UGI -0.09
- BPMC -0.97
- Stochastic Oscillator
- UGI 45.31
- BPMC 87.41
About UGI UGI Corporation
UGI Corp is an American holding company that, through its subsidiaries, is involved in the transport and marketing of energy and related services. Its segments include AmeriGas Propane, UGI International, Midstream & Marketing, and Utilities. The AmeriGas Propane segment consists of the propane distribution business. The UGI International segment consists of LPG distribution businesses. The Midstream & Marketing segment consists of energy-related businesses. The Utilities segment consists of the regulated natural gas and electric distribution. The company derives a majority of its revenue from the UGI International segment.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.